Updates in the ABC5 guidelines for the treatment of luminal metastatic breast cancer
Updates in the ABC5 guidelines for the treatment of luminal metastatic breast cancer
Current controversies in breast cancer treatment
Highlights from BGICC 2020
PARP inhibitors and immunotherapy in ovarian cancer: From research to practice
The age of genomic profiling
Identifying BRCA mutations for breast and ovarian cancer
Long-term toxicities in paediatric ALL
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer
Novel therapeutic approaches in B-progenitor ALL
Latest concepts in frontline therapy for paediatric ALL
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients